21 citations
,
June 2017 in “Case Reports in Dermatology” Reducing gefitinib dosage improved hair loss, but scarring remained.
August 2016 in “PolyPublie (École Polytechnique de Montréal)” Doxorubicin causes heart damage, so early detection and monitoring are important during chemotherapy.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
21 citations
,
August 2002 in “British Journal of Ophthalmology” Drug misuse can cause serious eye infections and other severe side effects.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
Biorregulatory therapy significantly improved the dog's health, reversing previous issues and eliminating the need for ongoing medication.
2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
Researchers made new compounds that could potentially be developed into anticancer drugs.
1 citations
,
September 2021 in “Pharmaceutics” High-dose finasteride may help treat glioblastoma but needs localized delivery for effectiveness.
December 2022 in “Zenodo (CERN European Organization for Nuclear Research)” Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.
August 2013 in “Nature Reviews Drug Discovery” New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
January 2016 in “대한피부과학회지” Bortezomib chemotherapy can cause temporary skin rashes.
3 citations
,
November 2013 in “Journal of Stem Cells and Regenerative Medicine” Imaging intestinal stem cells might help detect early signs of colorectal cancer.
January 2016 in “한국공업화학회 연구논문 초록집” The nanoparticles show promise for cancer treatment and diagnosis with fewer side effects.
1 citations
,
April 1953 in “Acta Radiologica” Irradiating the whole central nervous system can lead to over 50% of patients with cerebellar medulloblastoma surviving three years.
43 citations
,
March 2017 in “Drug Design Development and Therapy” The new nanoparticles could improve melanoma treatment by working better than current options.
February 2025 in “Journal of Pharmaceutical and Health Research” Arumanis mango rind extract and its fractions can kill breast cancer cells, especially the ethanol extract and ethyl acetate fraction.
Some side effects of breast cancer chemotherapy last longer than others, and patient feedback can help improve care.
November 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
32 citations
,
March 2009 in “AAPS PharmSciTech” January 2024 in “Scripta Medica” Nanoparticle delivery can reduce side effects of the cancer drug doxorubicin.
3 citations
,
May 2016 in “International Journal of Research in Ayurveda and Pharmacy” Ayurveda, using herbs like ginger, garlic, and turmeric, can reduce chemo-radiotherapy side effects in cancer patients.
December 2023 in “Frontiers in oncology” Older ovarian cancer patients live longer and tolerate weekly chemotherapy better than three-weekly treatments.
July 2025 in “Journal of the Pakistan Medical Association” Combining TCA with 5-FU is more effective and safer for treating keloids than TCA alone.
June 2025 in “Veterinary Sciences” Oclacitinib effectively treated a diabetic cat's severe skin issues without raising glucose levels, and surgery fixed eyelid fusion.
59 citations
,
August 2018 in “The oncologist” Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.
2 citations
,
April 2025 in “Cureus” Ki-67 levels do not predict treatment response in triple-negative breast cancer.
1 citations
,
June 2024 in “Journal of Clinical Oncology” Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.